Thanks for the link, ashleyk.

As it says in your linked article, "CuATSM is a small artificial molecule [that contains a copper atom,] that is able to deliver copper to cells containing damaged mitochondria ...".

As it says in the Conclusions section of the PD Phase 1 abstract (see link above): "Based on treatment tolerance and improvement in UPDRS and PDQ-39 over 24 weeks at [recommended dose], further development in a randomized, placebo-controlled trial is justified."